Vitiligo
☆ I dtorthaí 2022 Stiftung Warentest ón nGearmáin, ní raibh sástacht na dtomhaltóirí le ModelDerm ach beagán níos ísle ná mar a bhí le comhairliúchán teileamhíochaine íoctha.
Tá sé níos deacra vitiligo na méara a chóireáil ná réimsí eile. Seachas a bheith mímhaiseach ó thaobh cosmaidí de, tá vitiligo gnáth agus níl sé tógálach. I deirmeolaíochta, is é an chóireáil is éifeachtaí ná phototherapy nó cóireáil léasair (excimer) 2-3 huaire sa tseachtain ar feadh 1 bhliain ar a laghad. Mura féidir leat dul chuig an ospidéal go minic ar chúiseanna airgeadais nó toisc go bhfuil tú gnóthach, is féidir leat triail a bhaint as meaisín fótaiteiripe atá ceadaithe le húsáid sa bhaile.
Eyelid vitiligo
Vitiligo ar láimh
References
Is neamhord craiceann coitianta é Vitiligo a fhágann paistí de chraiceann bán mar gheall ar chailliúint melanocytes. Léiríonn taighde le déanaí gur galar uath-imdhíonachta é. Cé go bhfeictear go minic gur ceist chosmaideach é, is féidir leis cur isteach go mór ar fholláine mheabhrach agus ar shaol laethúil. In 2011, rinne saineolaithe rangú ar chineál ar a dtugtar segmental vitiligo ar leithligh ó chinn eile.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Tá roinnt roghanna teiripe ag othair vitiligo gníomhacha, mar shampla glucocorticoids sistéamach, fótaiteiripe, agus imdhíon-bhrúnna sistéamach. D’fhéadfadh go bhfaighidh othair vitiligo cobhsaí faoiseamh ó corticosteroidí tráthúla, coscairí cailcínithe i mbéal an phobail, fótaiteiripe, agus nósanna imeachta trasphlandúcháin. Tá forbairt teiripí spriocdhírithe mar thoradh ar dhul chun cinn le déanaí maidir le próisis bhunúsacha Vitiligo a thuiscint. Faoi láthair, is iad na coscóirí JAK na cinn is bisiúla, rud a thairgeann dea-fhulangacht agus torthaí feidhmiúla, in ainneoin an riosca go ndéanfaí ionfhabhtuithe folaigh agus fo-iarmhairtí sistéamacha atá coitianta le gníomhairí imdhíon-bhrú eile a ghníomhachtú. Tá sé mar aidhm ag taighde leanúnach príomhchítocíní a aithint a bhfuil baint acu le forbairt vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . Tá gealltanas léirithe ag blocáil na cítocíní seo i múnlaí ainmhithe agus i roinnt othar. Ina theannta sin, tá imscrúduithe ar miRNA-based therapeutics agus adoptive Treg cell therapy ar siúl.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Níl aon leigheas aitheanta ar vitiligo. Dóibh siúd a bhfuil craiceann éadrom acu, is gnách go moltar grianscéithe agus makeup. D’fhéadfadh uachtair stéaróideacha nó fótaiteiripe a bheith i gceist le roghanna cóireála eile.
○ Cóireáil
#Phototherapy
#Excimer laser
#Tacrolimus ointment